Healthcare Providers and Services
Company Overview of St. Jude Children's Research Hospital, Inc.
St. Jude Children's Research Hospital, Inc. operates a pediatric treatment and research facility. It also engages in the research and treatment of blood disorders, cancer, and infectious diseases in children. St. Jude Children's Research Hospital, Inc. was formerly known as St Jude Children's Research Hospital, Memphis, Tennessee. The company was founded in 1959 and is based in Memphis, Tennessee.
262 Danny Thomas Place
Memphis, TN 38105
Founded in 1959
Key Executives for St. Jude Children's Research Hospital, Inc.
Chief Executive Officer and President
Chief Legal Officer and Senior Vice President
Chief Communications Officer and Senior Vice President
Chief Nursing Officer and Senior Vice President of Patient Care Services
Compensation as of Fiscal Year 2016.
St. Jude Children's Research Hospital, Inc. Key Developments
St. Jude Children's Research Hospital Appoints James Morgan as Scientific Director and Executive Vice President
Aug 24 16
St. Jude Children's Research Hospital has named James Morgan, Ph.D., scientific director and executive vice president. Morgan held the interim scientific director post since 2015, and was formerly chair of the Department of Developmental Neurobiology. As scientific director, Morgan will oversee the institution's basic science programs and related research efforts. The appointment comes as St. Jude takes steps to strengthen its basic research programs to advance the fight against childhood cancer and other life-threatening diseases.
St Jude Children's Research Hospital Names Michael Dyer as Chair of the Department of Developmental Neurobiology
Jun 8 16
St Jude Children's Research Hospital named Michael Dyer, Ph.D., chair of the Department of Developmental Neurobiology. Dyer, who joined St. Jude in 2002 as an assistant member in Developmental Neurobiology, has received numerous awards for his work. Dyer's current research is focused on understanding how retinal progenitor cells coordinate proliferation and cell fate specification during development, and how genetic alterations in solid tumors, particularly retinoblastoma, can provide leads for the development of new therapeutic approaches.
NanoViricides Signs Agreement with St. Jude Children's Research Hospital for Further Influenza Drug Development
May 31 16
NanoViricides, Inc. announced that it has entered into an agreement with St. Jude Children's Research Hospital for further drug development in its anti-influenza program. NanoViricides, Inc. has previously held a pre-IND meeting with the US FDA on its anti-influenza drug development program, and obtained valuable guidance. Since then, the Company has been performing necessary CMC (chemistry, manufacture, and control) studies and production scale-up for the identified development candidate, namely, FluCide™-I. The Company has also continued further anti-influenza drug development that is anticipated to result in additional candidates superior to FluCide-I. The testing of these candidates for anti-influenza activity will be performed in the laboratory of Dr. Elena Govorkova in collaboration with Dr. Robert G. Webster and will include both in vitro and in vivo studies. They have extensive experience in influenza virus infections with a large number of different influenza strains, and in anti-viral agents discovery. The overall objective of these studies will be to help select clinical drug development candidates for the treatment of influenza virus in humans, using both the injectable and oral administration routes. Injectable administration is preferable for hospitalized patients that are extremely sick, while oral administration is preferred for out-patients. The in vitro studies will evaluate the efficacy and potency of the Company's nanoviricides anti-viral agents against a panel of influenza A and B virus infection of different types of cells, including human bronchial epithelial cells. The in vivo studies in small animals will evaluate the safety and efficacy of the Company's nanoviricides to protect against severe H1N1 influenza infection.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|